|
May 2
|
Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High?
|
|
Apr 12
|
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
|
|
Apr 11
|
Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why
|
|
Apr 5
|
Praxis Precision Medicines to Participate in Upcoming April Conferences
|
|
Mar 29
|
Health Care Roundup: Market Talk
|
|
Mar 28
|
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
|
|
Mar 28
|
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
|
|
Mar 27
|
Praxis (PRAX) Surges on Positive Epilepsy Study Results
|
|
Mar 26
|
Top 1% Biotech, Praxis, Releases 'Fireworks' And Catapults To Year-High
|
|
Mar 26
|
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
|
|
Mar 25
|
Praxis Precision Medicines to Host PRAX-628 Program Update
|
|
Mar 25
|
A Look At The Intrinsic Value Of Praxis Precision Medicines, Inc. (NASDAQ:PRAX)
|
|
Mar 8
|
What Makes Praxis Precision Medicines, Inc. (PRAX) a Strong Momentum Stock: Buy Now?
|
|
Mar 7
|
Praxis Precision Medicines Inc (PRAX) Reports Full-Year 2023 Financial Results and Corporate Updates
|
|
Mar 6
|
Wall Street Analysts Think Praxis Precision Medicines, Inc. (PRAX) Could Surge 134.35%: Read This Before Placing a Bet
|
|
Mar 5
|
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 5
|
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
|
|
Feb 13
|
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is definitely on the radar of institutional investors who own 47% of the company
|
|
Feb 2
|
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jan 11
|
Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering
|